The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data
Open accessAbstract
Background: Relapse is common in major depressive disorder (MDD). In this study, we evaluated the incremental health care burden of relapse in patients with MDD. Methods: This real-world retrospective cohort study used administrative medical and pharmacy claims data to identify commercially insured adult patients in the United States diagnosed with MDD who initiated a new antidepressant between January 1, 2012, and September 30, 2017. All-cause health care resource utilization, total costs, and medication adherence were evaluated in two cohorts: patients with and patients without relapse. Relapse was defined as suicide attempts, psychiatric hospitalization, mental health–related emergency department (ED) visit, use of electroconvulsive therapy, or reinitiation of treatment after a gap ≥6 months. Results: The study population included 14,186 patients (7093 baseline-matched patients per cohort). The mean follow-up period was 27.5 and 26.0 months for patients with and patients without relapse, respectively. Patients with relapse had significantly higher rates of hospitalization (16.6% vs 8.5%; p < .0001) and ED visits (54.8% vs 34.7%; p < .0001) than patients without relapse. The total costs for patients with relapse were significantly higher ($12,594 vs $10,445; p < .0001). Patients with relapse were also less adherent to antidepressants (mean proportion of days covered, 0.43 vs 0.49; p < .0001). Conclusions: Relapse of MDD was associated with increased total costs and health care utilization and lower adherence to antidepressants. Reducing the risk of relapse may result in a reduction of the associated health care burden; however, findings may only be generalizable to patients with commercial insurance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is estimated that up to 50-80% of patients who have experienced a major depressive episode will experience at least one relapse in their lifetime (1).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other studies (1, 3, 19–29, 50–55), however, establish as criteria only factors that are more administrative than clinical, such as the increase in referrals or reinitiation of treatments, which, on the contrary, has the advantage of being purely descriptive but with a risk of underdiagnosing relapses (4).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and necessity of ECT 13 times (1, 8, 16, 17, 19, 21, 26, 27, 38, 40, 46, 48, 50, 52).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, multiple studies have shown a statistically significant association between relapse and hospitalization or emergency presentations (1).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“patients who experience relapses consume a greater amount of health resources, which translates into a higher annual cost both in total and in relation to MDD (1).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [1]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Risk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023 · cited 1×
“However, evidence suggests that 30% to 85% of patients experience a relapse or recurrence of MDD [5, 6].”
BackgroundMultiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835 · cited 1×
“Data indicate that the risk of a subsequent recurrence increases by 16% after each recurrence [7].”
BackgroundMelfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1128 · Cited by 409 · cited 1×
“This definition has been used previously in published methodology to define relapse in MDD using claims data [11].”
MethodBuckman, J. E. J., Underwood, A., Clarke, K., Saunders, R., Hollon, S. D., Fearon, P., & Pilling, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.07.005 · Cited by 398 · cited 1×
“Risk factors for recurrence include the presence of residual symptoms despite antidepressant therapy, a history of previous recurrence, a history of or current comorbid anxiety disorder, and a history of child maltreatment or abuse [8].”
BackgroundSim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · cited 4×
“In one study, the median time to recurrence was approximately 40 months in patients continuing therapy, compared with a little over 1 year in patients who discontinued antidepressant therapy [6].”
BackgroundResultInfluentialHo, S. C., Chong, H. Y., Chaiyakunapruk, N., Tangiisuran, B., & Jacob, S. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.12.029 · Cited by 186 · cited 2×
“Although antidepressants effectively reduce the risk of relapse [6], relapse rates are higher in patients on antidepressants who are not adherent or who discontinue treatment early than in those who use antidepressants as directed [9].”
BackgroundKeyloun, K. R., Hansen, R. N., Hepp, Z., Gillard, P., Thase, M. E., & Devine, E. B. (2017) · CNS Drugs · doi:10.1007/s40263-017-0417-0 · Cited by 99 · cited 4×
“At 1 year, only 17% were persistent with SSRI therapy, 22% with SNRI therapy, and 9% with TCAs [10].”
BackgroundInfluential
Cited by
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“High relapse rates correlate with increased public health burden, hospitalization, and costs [24].”
BackgroundHabets, P. C., Thomas, R. M., Milaneschi, Y., Jansen, R., Pool, R., Peyrot, W. J., Penninx, B. W. J. H., Meijer, O. C., van Wingen, G. A., & Vinkers, C. H. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.05.024 · Cited by 37
“To what extent the described predictive signature generalizes to longer remission rates remains to be seen and may not hold given that an approximated 30% to 85% of remissions in depression are followed up by a relapse at some point (57).”
Ju, Y., Wang, M., Liu, J., Liu, B., Yan, D., Lu, X., Sun, J., Dong, Q., Zhang, L., Guo, H., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291722002628 · Cited by 26
“Treatment non-response and recurrence were reportedly the main contributors to the disease burden in patients with MDD (Dennehy et al., 2015; Gauthier, Mucha, Shi, & Guerin, 2019; Touya et al., 2022).”
Vasiliu, O. (2023) · Pharmaceuticals · doi:10.3390/ph16030411 · Cited by 22
“At a practical level, despite quite a large armamentarium of pharmacological agents for MDD, there is an important percentage of patients who did not reach remission or have a high relapse rate [74,75].”
BackgroundRonold, E. H., Myklebost, S. B., & Hammar, Å. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1163073 · Cited by 11
“Groups (males) Completers n = 10 (4) Drop out 2 years n = 9 (2) Drop from intervention n = 10 (4)”
Background
Metadata
- Authors
- Touya, M., Lawrence, D. F., Kangethe, A., Chrones, L., Evangelatos, T., & Polson, M.
- Affiliations
- Lundbeck (United States) (US)
- Corresponding author
- Touya, Maëlys
- Venue
- BMC Psychiatry
- Published
- 2022-03-01
- Volume
- 22
- Issue
- 1
- Pages
- 152-152
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC8886836
- OpenAlex
- W4214552469
- Cited by
- 21
- References
- 13
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Takeda Pharmaceuticals U.S.A.
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- major depressive disorder, relapse, healthcare burden, health care utilization, health care costs, antidepressant adherence, psychiatric hospitalization, emergency department visits, suicide attempts, electroconvulsive therapy, private insurance
- MeSH terms
- Adult, Antidepressive Agents, Chronic Disease, Depressive Disorder, Major, Major Depressive Disorder, Humans, Recurrence, Retrospective Studies, United States, Cohort Studies, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data. https://app.cochat.ai/papers/10.1186/s12888-022-03793-7
- The paper
- Touya, M., Lawrence, D. F., Kangethe, A., Chrones, L., Evangelatos, T., & Polson, M. (2022). Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data. BMC Psychiatry. https://doi.org/10.1186/s12888-022-03793-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.